OrbiMed is an investment manager focused exclusively on the healthcare sector. OrbiMed’s predecessor was founded in 1989, and OrbiMed is owned by Sven H. Borho, Carl L. Gordon, Jonathan T. Silverstein, W. Carter Neild, Geoffrey C. Hsu, C. Scotland Stevens, and David P. Bonita. As of December 31, 2018 OrbiMed, together with its affiliates and relying advisers, managed approximately $11.4 billion on a discretionary basis on behalf of 23 clients.

OrbiMed provides discretionary investment management services to U.S. and non-U.S. public and private funds. In providing such services, OrbiMed utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. Such strategies generally include, within the healthcare sector and subject to the investment program of each client, investments in the securities of U.S. and non-U.S. public and/or private companies. Clients are permitted to set guidelines for their accounts which customize OrbiMed’s core strategies, including restrictions related to sub-sector, geographic and other weightings. In providing its investment advisory services, OrbiMed determines when and which investments will be acquired, disposed of, or exchanged on behalf of its clients to maintain a portfolio consistent with each client’s objectives. please register to get more info

Open Brochure from SEC website
Pooled Investment Vehicles $14,910,510,000
Discretionary $14,910,510,000
Non-Discretionary $
Registered Web Sites

Related news

Bristol Myers Squibb Co.

1 Day BMY -0.31% DJIA -0.34% S&P 500 -0.19% Health Care/Life Sciences 0.49%

Covid Shined Light on Biotech, and Bulls See Even Brighter 2021

a biotech fund manager for OrbiMed Advisors. “This is not a sector that is dependent on Covid to generate returns.”

Fusion Pharmaceuticals Inc

2020 WILL ENABLE CO TO FUND ITS OPERATIONS INTO 2024. Orbimed Advisors Reports Stake In Fusion Pharmaceuticals Of 7.2% July 7 (Reuters) - Fusion Pharmaceuticals Inc <FUSN.O>::ORBIMED ADVISORS ...

Sam Sia’s NY Biotech Incubator Already Bustling With 16 Startups

“With the help I’m getting here, I’ll be able to fund this work sooner or later ... capitalists (New Leaf Venture Partners, OrbiMed Advisors), representatives from pharmaceutical companies ...

Is LogicBio Therapeutics, Inc. (LOGC) Going to Burn These Hedge Funds?

According to Insider Monkey’s hedge fund database, OrbiMed Advisors, managed by Samuel Isaly, holds the biggest position in LogicBio Therapeutics, Inc. (NASDAQ:LOGC). OrbiMed Advisors has a $58 ...

Breakingviews - Chinese vaccine developer flags corporate disease

HONG KONG (Reuters Breakingviews) - A once-in-a-lifetime pandemic opportunity is being undermined by an equally rare corporate governance disaster. Sinovac Biotech’s Covid-19 vaccine tests were ...

Hedge Funds Have Never Been This Bullish On Arcturus Therapeutics Holdings Inc. (ARCT)

That’s why we believe hedge fund sentiment is an extremely useful ... Other investors bullish on the company included OrbiMed Advisors, Point72 Asset Management, and DAFNA Capital Management.

AtriCure Inc. (NASDAQ:ATRC) Shares Acquired by Fmr LLC

Fmr LLC raised its stake in shares of AtriCure Inc. (NASDAQ:ATRC) by 34.6% in the second quarter, Holdings Channel.com reports. The fund owned 4,766,815 shares of the medical device company’s stock after purchasing an additional 1,

Strictly Legal: Report on sexual harassment allegations not defamatory

Sam Isaly is the founder and former Managing Partner of OrbiMed Advisors, LLC, a hedge fund that invests in healthcare and biotechnology companies. Isaly is quadriplegic due to an athletic injury ...

Hedge Funds Are Done Buying Xenon Pharmaceuticals Inc (XENE)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter.
No recent news were found.